Q&A: How Pharmacists Can Use AI to Humanize Care
Scott Nelson, PharmD, MS, FAMIA, ACHIP, joined Drug Topics to discuss the 2025 Pharmacy Forecast and AI’s role in the future of pharmacy practice.
Black Rural Patients Experience Higher Mortality Risk for Health Care-Associated Infection
Investigators also find that the proportion of patients that were admitted to the intensive care unit after hospital admission was much higher for Black rural patients.
Digital Education Games Could Help Improve Diabetes Management in Children
Children with type 1 diabetes who watched educational videos and played games had improved glycemic control and quality of life.
RFK Jr Says Trump Administration ‘Committed’ to PBM Reform
As a new presidential administration begins to take shape, experts are curious about its promises of potential PBM reform within the pharmacy benefits industry.
Biofeedback Shows Promising Results in Treating Chronic Pain
In a systematic review, researchers explored how biofeedback impacted rehabilitation in patients experiencing chronic pain disorders.
FDA Approves Ranibizumab Injection for Diabetic Macular Edema
The therapy is now the first and only FDA-approved treatment that maintains vision with fewer treatments compared to standard-of-care injections.
Newer Diabetes Medications Associated With Lower Risk of MACE, Reductions in Hemoglobin A1c
Sodium-glucose cotransporter 2 inhibitors are more cardioprotective in older adults and glucagon-like peptide-1 receptor agonists for younger patients.
Q&A: How Bringing Medical Students Into the Pharmacy Can Enhance Collaboration
Rebecca Lahrman, PharmD, MS, BCACP discusses her time as a preceptor and what she learned from the experience.
Q&A: Regulatory, Administrative Framework Creates Barriers for Health-System Pharmacy
Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, discussed tactics and challenges health-system pharmacy encounters within the distribution of patient benefits.
Patients with Obesity Showed High Discontinuation, Low Reinitiation of GLP-1 RAs
Researchers addressed the factors leading to and the rates of discontinuation and reinitiation of GLP-1 RAs among adults with obesity.
FDA Approves Apomorphine for Treatment of Motor Fluctuations in Parkinson Disease
The drug will be made available in the second quarter of 2025.
Amazon Pharmacy’s Subscription Service Associated With Improved Medication Adherence, Reduced Costs
Approximately 29% of patients were also more likely to refill their medication, leading investigators to consider an association between medication adherence.
Q&A: Pharmacists’ Role in Helping Patients Manage Ultra-High-Cost Drugs
Erin Fox, PharmD, MHA, BCPS, FASHP, joined Drug Topics to explore ultra-high-cost drugs and pharmacists’ role in managing patients’ prescription regimens.
Subcutaneous Amycretin Shows Weight Loss of 9.7% for 20 Weeks
In a phase 1b/2a clinical trial, investigators evaluated the once weekly subcutaneous drug for safety, tolerability, pharmacokinetics, and proof-of-concept.
Semaglutide Does Not Increase Depression, Suicidal Ideation in Patients With Obesity
Taking once-weekly subcutaneous semaglutide does not increase depression symptoms or suicidal ideation in patients with obesity.
COVID-19 Had Worst Disease Outcomes Among Respiratory Viruses
In their exploration of 2 separate respiratory virus seasons, researchers examined the severity of illness for SARS-CoV-2, influenza, and respiratory syncytial virus.
Defining Resilience in Adolescents with Type 1 Diabetes
There is no standard way to define resilience in adolescent patients with type 1 diabetes, though many studies see resilience as an ability or process.
FDA Approves Actemra Biosimilar Tocilizumab-Anoh
Tocilizumab-anoh is the biosimilar formulation for ACTEMRA, a medication used to treat rheumatoid arthritis, COVID-19, and other diseases.
FDA Approves Meloxicam and Rizatriptan For Acute Treatment of Migraine
Axsome Therapeutics expects the therapy to be commercially available in the United States in approximately 4 months.
FDA Approves Suzetrigine For Treatment of Acute Pain
The decision makes the selective NaV1.8 pain signal inhibitor the first new class of medicine to treat acute pain in over 20 years.
Medicare Drug Price Negotiations Expose Community Pharmacies to Financial Risk
A survey conducted by 3 Axis Advisors revealed potential impacts of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.
Diabetes, Prediabetes Linked to Older Brain Age
Patients with diabetes and prediabetes have older brain ages than their chronological age compared with normoglycemic patients.
ASHP’s Outlook for the Pharmacy Profession in 2025
Joseph DiPiro, PharmD, FCCP, FAAAS, broke down the importance of the ASHP Pharmacy Forecast and the process in which its content is curated.
Q&A: Building a Better Future for Community Pharmacy
Jennifer Bacci, PharmD, MPH, discusses ways to improve current issues impacting community pharmacy.
Racial Disparities Significant in Children Receiving Nutrition, Lifestyle Counseling
In a post hoc secondary analysis of the BP-CATCH trial, researchers explored the best ways of screening children with high blood pressure and managing their care.
Obesity in Adolescents: Prevalence, Health Effects, and Treatment Options
Adolescent obesity rates have risen in recent years, and a number of treatment options can be taken to help reduce the risk of a variety of associated medical problems.
Micronutrient Deficiencies Common Among Patients With Type 2 Diabetes
A recent systematic review and meta-analysis found that almost half of all patients with type 2 diabetes were deficient in multiple micronutrients.
Q&A: Raising Awareness About Maternity Care Deserts Among Community Pharmacists
Natalie DiPietro Mager, PharmD, PhD, discusses the role of community pharmacy in maternal health.
Q&A: The Rise of AI in Alleviating Health Care Workforce Challenges
Scott Nelson, PharmD, MS, FAMIA, ACHIP, discussed the increasingly crucial role artificial intelligence has played in streamlining pharmacy services.
Gestational Age Associated with Pain Among Very Preterm Infants
Researchers analyzed liveborn infant data from January 2020 to June 2024 to determine prevalence, cause, and treatment strategies for pain among preterm infants.
